Abstract
Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
CNS & Neurological Disorders - Drug Targets
Title:Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
Volume: 15 Issue: 3
Author(s): Juan C. Jurado-Coronel, Marco Ávila-Rodriguez, Valentina Echeverria, Oscar Alejandro Hidalgo, Janneth Gonzalez, Gjumrakch Aliev and George E. Barreto
Affiliation:
Abstract: Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
Export Options
About this article
Cite this article as:
Jurado-Coronel C. Juan, Ávila-Rodriguez Marco, Echeverria Valentina, Hidalgo Alejandro Oscar, Gonzalez Janneth, Aliev Gjumrakch and Barreto E. George, Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease , CNS & Neurological Disorders - Drug Targets 2016; 15 (3) . https://dx.doi.org/10.2174/1871527315666160202125519
DOI https://dx.doi.org/10.2174/1871527315666160202125519 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry The Importance of Steroidomics in the Study of Neurodegenerative Disease and Ageing
Combinatorial Chemistry & High Throughput Screening Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science Design and Microwave-Assisted Synthesis of Aza-Resveratrol Analogs with Potent Cholinesterase Inhibition
CNS & Neurological Disorders - Drug Targets Benefit of 13-desmethyl Spirolide C Treatment in Triple Transgenic Mouse Model of Alzheimer Disease: Beta-Amyloid and Neuronal Markers Improvement
Current Alzheimer Research Essential Oils as Active Ingredients of Lipid Nanocarriers for Chemotherapeutic Use
Current Pharmaceutical Biotechnology The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Current Signal Transduction Therapy Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets The Contribution of Extracellular Nef to HIV-Induced Pathogenesis
Current Drug Targets